A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

This will be a Phase 1, open-label, 2-period, 2-treatment, fixed-sequence, cross-over study
in approximately 12 healthy subjects employing administration of a single oral dose of
PF-06463922 in the fasted state alone, and with multiple dosing of rifampin 600 mg once a day
to estimate the effect of multiple dose rifampin on the single dose PK of PF-06463922.

Inclusion Criteria:

- Healthy female subjects of non-childbearing potential and/or male subjects who, at the
time of screening, are between the ages of 18 and 55 years, inclusive

- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)

Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease

- Any condition possibly affecting drug absorption

- Positive urine drug screen

- History of HIV, Hep B or Hep C

- History of regular alcohol consumption

- History of cardiac arrhythmia, history of AV block, history of symptomatic
bradycardia, history of QTc prolongation

- History of pancreatitis or hyperlipidemia, elevated lipase